Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New thrombolytic drugs.

A Thomson1

  • 1Royal Hobart Hospital, Tasmania.

Australian and New Zealand Journal of Medicine
|June 27, 2000
PubMed
Summary
This summary is machine-generated.

New thrombolytic drugs aim for improved efficacy and safety in dissolving blood clots, targeting myocardial infarction treatment. Research explores novel agents, including engineered proteins and animal-derived compounds, to overcome limitations of current therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance.

The Journal of urology·2023
Same author

Out of our comfort zone.

British dental journal·2020
Same author

Patient blood management - a new paradigm for transfusion medicine?

ISBT science series·2020
Same author

Recruitment and retention.

British dental journal·2020
Same author

Adapting to current trends.

British dental journal·2019
Same author

Enhanced monocyte recruitment and delayed alternative macrophage polarization accompanies impaired repair following myocardial infarction in C57BL/6 compared to BALB/c mice.

Clinical and experimental immunology·2019

Area of Science:

  • Cardiovascular Pharmacology
  • Biochemistry
  • Drug Discovery

Background:

  • Thrombolytic drugs are crucial for reducing mortality in myocardial infarction.
  • Current agents have limitations, driving research for improved treatments.
  • The ideal thrombolytic agent offers rapid, complete, and safe clot dissolution.

Purpose of the Study:

  • To review emerging classes of thrombolytic agents.
  • To highlight advancements in drug design for enhanced efficacy and safety.
  • To discuss the potential of novel compounds in treating thrombotic events.

Main Methods:

  • Review of current research on novel thrombolytic drug development.
  • Categorization of new agents into five broad groups: urokinase variants, tissue plasminogen activator variants, chimeric activators, antibody conjugates, and animal-derived compounds.

Related Experiment Videos

  • Analysis of molecular modifications and targeting strategies for improved performance.

    • Main Results:

    • Novel agents include engineered plasminogen activators (mutants, chimeras), antibody-drug conjugates, and substances from vampire bats, snakes, and bacteria.
    • Modifications aim to increase half-life, resistance to inhibitors, fibrin binding, and clot targeting.
    • These advanced agents are largely untested in clinical trials.

    Conclusions:

    • Current thrombolytic therapies have significant limitations.
    • Novel thrombolytic agents show promise but require clinical validation.
    • Future strategies may involve combination therapies with anti-platelet agents for superior outcomes.